As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing adoption in advanced treatment lines, CARVYKTI is poised for substantial revenue growth. LAS...
Read More Details
Finally We wish PressBee provided you with enough information of ( CARVYKTI Continued Performance Reflects Growing Confidence in CAR-T Therapies for Multiple Myeloma .. DelveInsight )
Also on site :
- Uno de los médicos acusados de suministrar ketamina a Matthew Perry acepta declararse culpable, según muestra el documento
- ‘Like the world has forgotten us:’ As Iran-Israel conflict escalates, Gazans fear their suffering will become invisible
- In Q1 2025, enterprise SaaS M&A deal count hit 210, according to PitchBook